Technology
Health
Biotechnology
Ascendis Pharma
$128.969876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$128.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$4.31 (3.46%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ASND and other stocks, options, ETFs, and crypto commission-free!
About
Ascendis Pharma A/S American Depositary Shares, also called Ascendis Pharma, is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. Read More The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Employees
—
Headquarters
Hellerup, Capital Region
Founded
2006
Market Cap
5.43B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
215.24K
High Today
$129.64
Low Today
$124.57
Open Price
$125.09
Volume
87.42K
52 Week High
$131.76
52 Week Low
$53.21
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
Europe (Non-UK)
Europe
News
Seeking AlphaMay 20
Ascendis Pharma's TransCon shows favorable safety profile in late-stage study
Preliminary data from a Phase 3 clinical trial, fliGHt, evaluating the safety and tolerability of Ascendis Pharma's (NASDAQ:ASND) TransCon Growth Hormone in patients with pediatric growth hormone deficiency previously treated with commercially available daily growth hormone therapies showed a comparable safety profile.
Yahoo FinanceMay 6
What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ascendis Pharma A/S (NASDAQ:ASND) with a market-capitalization of US$5.7b, rarely draw their attention. However, history shows that overlooked mid-cap companies have performed better on a risk-adjusted manner than the smaller and larger segment of the market. Today we will look at ASND’s fin...
Price Paid on Robinhood
24% Higher
Right Now
52 Week Low
$53.21
Average Price Paid
$103.91
52 Week High
$131.76
Earnings
-$1.25
-$0.85
-$0.44
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
-$0.85 per share